Clinical trial
A Randomized, Double-blind, Parallel-group, Placebo and Active Comparator (Pioglitazone)-Controlled Clinical Study to Determine the Efficacy and Safety of Balaglitazone in Patients With Type 2 Diabetes on Stable Insulin Therapy
NCT00515632 is registered in ClinicalTrials.gov with Rheoscience A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Parallel-group, Placebo and Active Comparator (Pioglitazone)-Controlled Clinical Study to Determine the Efficacy and Safety of Balaglitazone in Patients With Type 2 Diabetes on Stable Insulin Therapy
- Lead sponsor
- Rheoscience A/S
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 31, 2007
- Completion date
- October 31, 2009
- Enrollment
- 409 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.